Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 17043297)

1.

Differential temporal expression of S100β in developing rat brain.

Patro N, Naik A, Patro IK.

Front Cell Neurosci. 2015 Mar 18;9:87. doi: 10.3389/fncel.2015.00087. eCollection 2015.

2.

Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia.

Aleksovska K, Leoncini E, Bonassi S, Cesario A, Boccia S, Frustaci A.

PLoS One. 2014 Sep 9;9(9):e106342. doi: 10.1371/journal.pone.0106342. eCollection 2014. Review.

3.

Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder.

van der Leeuw C, Marcelis M, Peeters SC, Verbeek MM, Menheere PP, de Haan L, van Os J, van Beveren NJ; Genetic Risk and Outcome in Psychosis (G.R.O.U.P.).

PLoS One. 2013 Dec 17;8(12):e82535. doi: 10.1371/journal.pone.0082535. eCollection 2013.

4.

Levels of S100B are raised in female patients with schizophrenia.

O'Connell K, Thakore J, Dev KK.

BMC Psychiatry. 2013 May 24;13:146. doi: 10.1186/1471-244X-13-146.

5.

Serum S100B represents a new biomarker for mood disorders.

Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K.

Curr Drug Targets. 2013 Oct;14(11):1237-48. Review.

6.

Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia.

Fineberg AM, Ellman LM.

Biol Psychiatry. 2013 May 15;73(10):951-66. doi: 10.1016/j.biopsych.2013.01.001. Epub 2013 Feb 12. Review.

7.

The evolution of S100B inhibitors for the treatment of malignant melanoma.

Hartman KG, McKnight LE, Liriano MA, Weber DJ.

Future Med Chem. 2013 Jan;5(1):97-109. doi: 10.4155/fmc.12.191. Review.

8.

S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway.

Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P.

Brain. 2012 Nov;135(Pt 11):3336-47. doi: 10.1093/brain/aws250.

9.

Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism?

Suchankova P, Klang J, Cavanna C, Holm G, Nilsson S, Jönsson EG, Ekman A.

J Psychiatry Neurosci. 2012 Feb;37(2):122-8. doi: 10.1503/jpn.110024.

10.

The Passage of S100B from Brain to Blood Is Not Specifically Related to the Blood-Brain Barrier Integrity.

Kleindienst A, Schmidt C, Parsch H, Emtmann I, Xu Y, Buchfelder M.

Cardiovasc Psychiatry Neurol. 2010;2010:801295. doi: 10.1155/2010/801295. Epub 2010 Jul 8.

11.

S100B Serum Levels in Schizophrenia Are Presumably Related to Visceral Obesity and Insulin Resistance.

Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, Walter M, Schroeter ML, Schwarz MJ, Bogerts B.

Cardiovasc Psychiatry Neurol. 2010;2010:480707. doi: 10.1155/2010/480707. Epub 2010 Jun 10.

12.

Mood disorders are glial disorders: evidence from in vivo studies.

Schroeter ML, Abdul-Khaliq H, Sacher J, Steiner J, Blasig IE, Mueller K.

Cardiovasc Psychiatry Neurol. 2010;2010:780645. doi: 10.1155/2010/780645. Epub 2010 May 27.

13.

Serum levels of S100B and NSE proteins in Alzheimer's disease patients.

Chaves ML, Camozzato AL, Ferreira ED, Piazenski I, Kochhann R, Dall'Igna O, Mazzini GS, Souza DO, Portela LV.

J Neuroinflammation. 2010 Jan 27;7:6. doi: 10.1186/1742-2094-7-6.

14.

Dysfunctions of neuronal and glial intermediate filaments in disease.

Liem RK, Messing A.

J Clin Invest. 2009 Jul;119(7):1814-24. doi: 10.1172/JCI38003. Epub 2009 Jul 1. Review.

15.

Evidence for a wide extra-astrocytic distribution of S100B in human brain.

Steiner J, Bernstein HG, Bielau H, Berndt A, Brisch R, Mawrin C, Keilhoff G, Bogerts B.

BMC Neurosci. 2007 Jan 2;8:2.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk